Who is sponsoring NCT05751421?

NCT05751421 is sponsored by Rothman Institute Orthopaedics.

What drugs are being tested in NCT05751421?

Interventions in NCT05751421: Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution, Bupivacaine HCl 0.5% Injectable Solution, primary total knee replacement.

What condition does NCT05751421 study?

NCT05751421 studies Pain, Postoperative.

Is NCT05751421 still recruiting?

NCT05751421 is currently status unknown. Last updated 2 March 2023.

Last reviewed 2023-03-02 · How we verify

NCT05751421

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pain Relief After PrimaryTKA

Status unknown Phase 3 Last updated 2 March 2023

What this trial tests

Phase 3 trial testing Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution in Pain, Postoperative in 60 participants. Status unknown.

Timeline

28 February 2023

Primary endpoint
28 February 2024

28 February 2024

Quick facts

Lead sponsor	Rothman Institute Orthopaedics
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	28 February 2023
Primary completion	28 February 2024
Estimated completion	28 February 2024
Sites	1 location across United States

Drugs / interventions tested

Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution — full drug profile →
Bupivacaine HCl 0.5% Injectable Solution — full drug profile →
primary total knee replacement

Conditions studied

Pain, Postoperative — all drugs for Pain, Postoperative →

Sponsor

Rothman Institute Orthopaedics

Who can join

18 and older, any sex, with Pain, Postoperative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

While a majority of people who undergo TKA have significant long-term improvement in functional ability, many patients may experience significant pain in the early postoperative period, which may adversely impact postoperative rehabilitation and recovery. Traditionally, opioid medications have been used to control postoperative pain. However, there are many risks with using opioid medications, including addiction and overdose, which kills over 48,000 people yearly. In an effort to overcome this, opioid-sparing multimodal analgesia (MMA) regimens have been developed, commonly using nonsteroid anti-inflammatory drugs (NSAIDs), acetaminophen, regional nerve blocks, and local anesthesia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pain, Postoperative

Currently open trials in the same condition.

NCT07512141 — Single Versus Double Drains in the Axillary and Pectoral Regions After Modified Radical Mastectomy · NA · recruiting
NCT07354581 — Erector Spinae Plane Block vs Quadro-Iliac Plane Block After Lumbar Instrumentation Surgery · NA · recruiting
NCT07239817 — PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach · NA · recruiting
NCT06740214 — Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty · Phase 3 · recruiting
NCT07057557 — Aloe Vera vs Paraffin Tulle Dressings for Pain Management in Split Thickness Skin Graft Donor Sites · NA · recruiting

Other Rothman Institute Orthopaedics trials

Trials by the same sponsor.

NCT06903767 — Automated V Manual Impactor Study · NA · enrolling by invitation
NCT06601803 — Surgiphor Us in TSA · Phase 4 · enrolling by invitation
NCT06575010 — Exparel v Dexamethasone in RCR · Phase 4 · enrolling by invitation
NCT06536842 — Wound Drain After Lumbar Fusion Surgery · NA · enrolling by invitation
NCT06484192 — Pain Control After Lumbar Spine Fusion · Phase 4 · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05751421 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rothman Institute Orthopaedics
Last refreshed: 2 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05751421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing